Stop Freaking Out About China By Nir Kaissar Nir

New Post Public Reply Private Reply Replies (0) Message Board
fitzkarz
Stop Freaking Out About China
By Nir Kaissar

Nir Kaissar is a Bloomberg Gadfly columnist covering the markets. He is the founder of Unison Advisors, an asset management firm. He has worked as a lawyer at Sullivan & Cromwell and a consultant at Ernst & Young.

Jan 4, 2016 1:02 PM EST

With China in the midst of what appears to be a significant economic slowdown, investors are questioning their faith in one of the new century's great growth stories. They shouldn't abandon China just yet.

First, some perspective. China was never going to string together an uninterrupted record of astounding annual growth. Despite all the hyperbole in recent years about China’s prowess and coming global dominance, not even China is exempt from the business cycle. But the current contraction will be followed by another expansion, unless you believe that China is going out of business -- and no one who is a serious student of the country and its economy believes that.
Big Time

Moreover, China is an authentic economic powerhouse. It’s one thing to post double digit annual GDP growth from a small base; it’s an entirely different matter to do so at critical mass. According to the IMF, China’s GDP in U.S. dollars in 1980 was $304 billion. The IMF estimates that China’s GDP in 2015 will be $11.4 trillion, roughly the size of the U.S.'s GDP in 2002! A decade ago no one expected the U.S. economy to grow at rates currently demanded of China.

It’s time to welcome China to the big leagues, and to stop pretending that its growth and stability should resemble those of an emerging market.
Real Thing
China's economic growth since 1980.
SOURCE: International Monetary Fund
IMF estimates of U.S. and China GDP for 2015.

If long-term investors agree that China is here to stay, there’s no cause for worry, let alone panic. But for those who still need convincing, let's do a little investment analysis. Over the long term, stock prices reflect earnings growth, which can be separated into three components: inflation, real productivity growth, and dividend yield. (The first two components represent nominal reinvestment of earnings, the latter represents the portion of earnings paid to shareholders.)

Here again, we have to be careful not to confuse yesterday’s China with today’s. Looking to IMF data, China’s inflation rate averaged 4.5 percent annually from 1990 to 2014. That is consistent with a fast growing emerging economy. During the five years ahead, the IMF estimates an average of 2.4 percent annually, which is consistent with a mature economy. Similarly, real productivity averaged 8.8 percent annually from 1990 to 2014, but is expected to be a more modest (but still enviable) 5.7 percent annually over the next five years. Finally, a realistic long term dividend yield is one that resembles that of large companies in a mature economy -- I would say 2 percent.

The sum of these three variables, 10.1 percent, is both the long term annual earnings growth and total return on investment that investors should demand of Chinese companies from today’s vantage. The inverse of 10.1 percent implies a fair value P/E of 9.9.

Now let’s look at how China is currently priced. But which China should we price? Should we look at the universe of Chinese companies owned by Chinese investors (A shares), or those owned by everyone else (H shares)? The question is far from trivial. The H shares, as represented by the Hang Seng Index, trade at a 9.4 P/E, while the A shares, as represented by the CSI 300 Index, trade at a 14.6 P/E.

There is another difference. Current profit margins of A shares are 19.6 percent higher than their average since 2006 (a full business cycle), whereas those of H shares are only 7.2 percent higher. This suggests that China’s feared slowdown has already meaningfully compressed the profitability of H shares, but not yet the profitability of A shares. And when earnings are normalized to reflect cyclically adjusted profit margins, A shares jump to a 17.5 P/E, whereas H shares barely budge to a 10.1 P/E.

Much of the feared China slowdown therefore appears to already be reflected in the fundamentals and stock prices of Chinese companies available to U.S. investors. With a P/E of 10.1 for H shares, a credible case can be made that the valuation already fully reflects investors’ fears about continuing economic weakness. I see no case for selling China's H shares at current levels, even if we assume that those fears will be realized.

China is a good, long-term play and much of the worry about its economy right now is noise.

http://www.bloomberg.com/gadfly/articles/2016...ock-market
I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 29

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 28

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 24

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 35

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 30

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 20

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Endava Investors: Legal Action Could Recover Your Losses

Updated Category News Views 87

Endava got tangled in a class action lawsuit over securities fraud back in 2024. Investors were already feeling the squeeze as whispers about declining demand for its services echoed through the trading floor. You know how it goes—when rumors hit, shares take a dive faster than you can blink. Class Action Reality: Who Gets to Play? The lawsuit targeted shareholders who...

Continue Reading
New Mortgage Ratings Assigned to Deephaven Trust Portfolio

Updated Category News Views 177

Introduction to Deephaven Residential Mortgage Trust 2024-1 In an important development within the non-prime mortgage market, KBRA has recently assigned preliminary ratings to eight classes of mortgage-backed notes from Deephaven Residential Mortgage Trust 2024-1 (DRMT 2024-1). This $514.6 million transaction comprises a unique pool of 1,330 residential mortgages,...

Continue Reading
Meta Platforms Declares Cash Dividend for Shareholders

Updated Category News Views 325

Quarterly Cash Dividend Announcement from Meta Platforms The board of directors of Meta Platforms, Inc. (NASDAQ: META) has recently declared a quarterly cash dividend of $0.525 per share, benefitting shareholders holding both Class A and Class B common stock. This dividend reflects the company's ongoing commitment to returning value to its shareholders. Dividend Payment...

Continue Reading
Campine Expects Strong Financial Upsurge in 2024 Performance

Updated Category News Views 125

Campine NV Forecasts Impressive Growth in 2024 Campine NV, a well-known name in the metals recycling and specialty chemicals sector, is gearing up for a promising financial year ahead. The company has recently indicated that it anticipates higher profits in 2024, thanks to favorable market conditions. Projected Revenue Growth for 2024 According to Campine's expectations,...

Continue Reading
Thumzup Media's Strategic Investment in Dogecoin Ahead of ETFs

Updated Category News Views 147

Thumzup Media's Strategic Move into Dogecoin Thumzup Media Corporation (Nasdaq: TZUP) has made headlines with its latest purchase of Dogecoin, securing around 7.5 million tokens valued at approximately $2 million. This significant acquisition marks the company's first open-market investment in Dogecoin, reflecting a strong belief in the digital currency's potential for...

Continue Reading